PMID- 33518629
OWN - NLM
STAT- MEDLINE
DCOM- 20211227
LR  - 20211227
IS  - 1884-2836 (Electronic)
IS  - 1344-6304 (Linking)
VI  - 74
IP  - 5
DP  - 2021 Sep 22
TI  - Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine 
      in Adults in Japan.
PG  - 399-404
LID - 10.7883/yoken.JJID.2020.947 [doi]
AB  - Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine 
      is generally used for booster vaccination of infants in Europe and the United 
      States to avoid increased reactogenicity after diphtheria and tetanus toxoids and 
      acellular pertussis (DTaP) vaccination. However, Japan has extended the use of 
      additional DTaP vaccination without reducing the antigen dose for diphtheria and 
      pertussis in adolescents and adults, despite limited reports on its safety in 
      adults. This prospective, observational, questionnaire-based study investigated 
      the occurrence of adverse events (AEs) following DTaP vaccination between June 
      2018 and June 2019 in participants aged 10 years or older. Of the 250 eligible 
      participants, 235 (94%) responded regarding AEs. Among them, 133 (56.6%) reported 
      AEs, of which 39 reported systemic AEs (16.6%) and 120 reported local AEs (51.1%) 
      attributed to DTaP vaccination. The incidence of local AEs was markedly higher 
      with DTaP vaccination than with non-DTaP vaccination (51.1% vs. 10.5%), and AEs 
      appeared later (P < 0.01) and lasted longer (P < 0.01) with DTaP vaccination. 
      However, more than 75% of these AEs resolved within 7 days. DTaP vaccination was 
      not associated with any serious AEs. These results indicate that the DTaP vaccine 
      can be widely used as a booster in adults as an alternative to the Tdap vaccine.
FAU - Ujiie, Mugen
AU  - Ujiie M
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
AD  - Department of Hygiene, Public Health and Preventive Medicine, Showa University 
      School of Medicine, Japan.
FAU - Tsuzuki, Shinya
AU  - Tsuzuki S
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
FAU - Suzuki, Michiyo
AU  - Suzuki M
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
FAU - Ota, Masayuki
AU  - Ota M
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
FAU - Suzuki, Tetsuya
AU  - Suzuki T
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
FAU - Nomoto, Hidetoshi
AU  - Nomoto H
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
FAU - Yamamoto, Kei
AU  - Yamamoto K
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
FAU - Saito, Sho
AU  - Saito S
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
FAU - Kokaze, Akatsuki
AU  - Kokaze A
AD  - Department of Hygiene, Public Health and Preventive Medicine, Showa University 
      School of Medicine, Japan.
FAU - Kinoshita, Noriko
AU  - Kinoshita N
AD  - Disease Control and Prevention Center, National Center for Global Health and 
      Medicine, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210129
PL  - Japan
TA  - Jpn J Infect Dis
JT  - Japanese journal of infectious diseases
JID - 100893704
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Diphtheria-Tetanus-Pertussis Vaccine)
RN  - 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
RN  - 0 (Toxoids)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Bacterial
MH  - Diphtheria/epidemiology/*prevention & control
MH  - Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage/*adverse effects
MH  - Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage/*adverse 
      effects
MH  - Humans
MH  - Immunization, Secondary
MH  - Incidence
MH  - Infant
MH  - Japan/epidemiology
MH  - Male
MH  - Prospective Studies
MH  - Tetanus/*prevention & control
MH  - Toxoids/administration & dosage/*adverse effects
MH  - Whooping Cough/epidemiology/*prevention & control
OTO - NOTNLM
OT  - DTaP vaccine
OT  - Japan
OT  - Tdap vaccine
OT  - booster vaccination
OT  - vaccine safety
EDAT- 2021/02/02 06:00
MHDA- 2021/12/28 06:00
CRDT- 2021/02/01 05:49
PHST- 2021/02/02 06:00 [pubmed]
PHST- 2021/12/28 06:00 [medline]
PHST- 2021/02/01 05:49 [entrez]
AID - 10.7883/yoken.JJID.2020.947 [doi]
PST - ppublish
SO  - Jpn J Infect Dis. 2021 Sep 22;74(5):399-404. doi: 10.7883/yoken.JJID.2020.947. 
      Epub 2021 Jan 29.